Despite the promise of IDO/TDO blockade in preclinical studies, a phase III clinical trial in unresectable melanoma found no difference in survival between IDO1 blockade with ICI therapy when compared to ICI therapy alone [20]. The gene discussed is TDO2; the disease is melanoma.